Slow progress on female leadership in oncology
Updated results from the ESMO Women for Oncology study monitoring the representation of women at major national and international congresses and societies
PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer